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Abstract 
We describe a 78-year-old Japanese patient with angiosarcoma on the scalp. Interestingly, 
immunohistochemical staining revealed this tumor as positive for matrix metalloproteinase 
9 (MMP-9). After conventional therapy for angiosarcoma with surgical treatment and 
radiation therapy, we intravenously administered docetaxel at 40 mg/m
2 body surface area 
together with oral administration of 17.5 mg sodium risedronate hydrate. One and a half 
years after the standard treatment, there was no evidence of local recurrence or metastasis. 
 
Introduction 
Angiosarcoma is a rare vascular tumor most frequently found on the face and scalp. 
It behaves highly aggressive and spreads widely throughout the skin, recurs locally, and 
metastasizes early [1]. Standard treatment with resection and adjuvant radiotherapy 
results in local control in approximately 50% of patients at 1 year and median survival 
is approximately 8 months [1–3]. Therefore, further adjuvant or supportive therapy is 
necessary for the treatment of angiosarcoma. 
Considerable evidence has implicated matrix metalloproteinases (MMP) in the 
degradation of the extracellular matrix (ECM) during the metastatic process [4]. 
Overexpression of MMP-9 has been demonstrated in human cancer. Murakami et al. [5] 
reported the expression of MMP-2 on subcutaneous angiosarcoma in canine. In human,  
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MMP-1 expression was detected in splenic angiosarcoma [6]. However, there is no 
English report suggesting the expression of MMP-9 on human angiosarcoma of the skin. 
In this report, we describe a case of angiosarcoma in which complete remission was 
archived with low dose docetaxel and bisphosphonate after the standard treatment of 
angiosarcoma. 
Case Report 
A 78-year-old woman consulted us with a 6-month history of an asymptomatic nodule on her 
scalp. Her nodule has been surgically resected at a private clinic 3 months before her visit. Two weeks 
after the resection, skin nodules had suddenly enlarged. On her first visit, physical examination 
revealed a skin-colored nodule with a surgery scar, teleangiectasia and purpura on her scalp (fig. 1). 
The tumor size was 16 mm in diameter. Histologically, irregular anastomosing vascular channels lined 
by single layers of enlarged endothelial cells existed between collagen bundles with dense infiltration 
of lymphocytes (fig. 2). Immunohistochemical staining revealed that these enlarged endothelial-like 
cells were strongly positive for CD31 and vimentin, and positive for Factor VIII and thrombomodulin, 
and negative for CD34, S-100, CK, SMA, and desmin. Moreover, these enlarged endothelial-like cells 
and tumor stromas were positive for MMP-9 (fig. 3) and negative for MMP-2 (data not shown). We 
used rabbit polyclonal anti-human MMP-9 antibody (Abcam, Tokyo, Japan) at a dilution of 1:100. In 
addition, we employed immunohistochemical staining for 9 cases of angiosarcomas that were 
histologically diagnosed in our institution, and about 78% (7/9) cases of angiosarcomas were positive 
for MMP9. From these results, we diagnosed this patient as MMP-9-expressing angiosarcoma. 
Positron emission tomography (PET) scans showed no evidence of metastases. We resected the tumor 
with a 3-cm surgical margin. After surgical treatment, the patient was treated with radiotherapy (70 
Gy). Then, we administered docetaxel monthly at 40 mg/m2 body surface area intravenously and 
weekly with oral administration of 17.5 mg sodium risedronate hydrate. One and a half years after the 
surgical treatment, there was no evidence of local recurrence or metastasis. 
Discussion 
In our present case, we describe a case of MMP-9-expressing angiosarcoma treated 
with low-dose docetaxel and bisphosphonate. Like paclitaxel, docetaxel promotes 
microtubule assembly and inhibits the depolymerization of tubulin, thus stabilizing 
microtubules, but docetaxel has a higher potency [4, 7, 8]. However, in studies 
conducted in Europe, docetaxel monotherapy was rather ineffective for soft-tissue 
sarcoma, including angiosarcoma, and could not be recommended for further use [9]. 
Therefore, further supportive reagents are necessary for the treatment of 
angiosarcoma with docetaxel. 
MMP-9 is a stromal factor that regulates the mobilization of hematopoietic stem cells 
from the bone marrow niche by solubilizing the membrane-bound form of c-KitL [10]. 
Because it remodels the extracellular matrix and promotes the sprouting and growth of 
new blood vessels by making VEGF available to the VEGFR-2/flk receptor on 
endothelial cells, MMP-9 is a linchpin in tumor progression [10]. Moreover, recently, 
several reports revealed the expression of MMP-9 on tumor correlated with the 
progression or prognosis of several skin tumors such as malignant melanoma, 
squamous cell carcinoma, basal cell carcinoma, and mycosis fungoides [11–14]. In 
addition, Koontz et al. [3] reported two cases of successful treatment of angiosarcoma 
with the administration of the anti-VEGF antibody bevacizumab along with 
radiotherapy prior to surgery. More recently, it was reported that pharmacological 
inhibition of MMP-9 by amino-bisphosphonate decreased pro-MMP-9 and VEGF in the  
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serum and abrogated the induction of immunosuppressive macrophages, myeloid-
derived suppressor cells (MDSCs), in the tumor microenvironment [15, 16]. In 
aggregate, inhibition of MMP-9 by bisphosphonate could be one of the optimal 
supportive therapies for the treatment of angiosarcoma by inhibiting tumor-induced 
angiogenesis and by the induction of anti-tumor immunity. 
In conclusion, the combination of docetaxel with bisphosphonate was effective for 
MMP-9-expressing angiosarcoma and resulted in complete remission after the standard 
therapy for angiosarcoma. Further study is needed to confirm this limited observation. 
 
 
 
 
 
 
Fig. 1. A skin-colored nodule with surgery scar, teleangiectasia and purpura on the scalp. 
 
 
 
Fig. 2. Irregular anastomosing vascular channel lined by a single layer of enlarged endothelial cells 
between collagen bundles with dense infiltration of lymphocytes. (a ×50; b ×200; original 
magnification). 
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Fig. 3. Enlarged endothelial-like cells and tumor stromas were positive for MMP-9. (×200; original 
magnification). 
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